Trial
NCT00867308
Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
—
Condition
Myelodysplastic Syndrome
Intervention
Lenalidomide 50 mg
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-17